Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Fallopian Tube Neoplasms 3Small Cell Lung Carcinoma 2Sarcoma 2Neoplasms 2Neoplasm Metastasis 2Carcinoma, Ovarian Epithelial 2Breast Neoplasms 2Uveal Melanoma 1Recurrence 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neurofibrosarcoma 1Melanoma 1Gastrointestinal Stromal Tumors 1Disorders of Sex Development 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Ipilimumab 98pembrolizumab 84Nivolumab 82aldesleukin 51Cyclophosphamide 49Interleukin-2 38fludarabine phosphate 31Vemurafenib 31Dacarbazine 31dabrafenib 29trametinib 28Temozolomide 26fludarabine 25CTLA-4 Antigen 18Bevacizumab 18Radiosurgery 15Paclitaxel 15Carboplatin 14encorafenib 13binimetinib 13Introns 13talimogene laherparepvec 12Radiotherapy 12Interferon alpha-2 12spartalizumab 11cobimetinib 10atezolizumab 10sargramostim 9peginterferon alfa-2b 9montanide ISA 51 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Melanoma × STA 9090 × Clear all
NCT01551693 2017-04-12

STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma

Dana-Farber Cancer Institute

Phase 2 Terminated
3 enrolled 7 charts
Dermatologic

Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡